
Scandinavian ChemoTech - Weathering the storm

Redeye provides a research update on Scandinavian ChemoTech following the Q4 2023 report and the retracted sales target in India. The company delivered a quarterly report that fell short of Redeye's estimates. Sales came in lower than anticipated, and OPEX was slightly higher, most likely due to some one-off items. On a positive note, a fifth commercial installation has been carried out on the US market and a TAM-expanding amendment to the study protocol at AIIMS Jodhpur has been announced.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Scandinavian ChemoTech - Weathering the storm](#)